NCT04459767View on ClinicalTrials.gov

Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
Healthy
Interventions
DRUG

Vupanorsen

80 mg subcutaneous injection

DRUG

Placebo

Subcutaneous injection

Trial Locations (1)

192-0071

P-one Clinic, Hachioji-shi

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04459767 - Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides | Biotech Hunter | Biotech Hunter